What the studies show
Allergic reactions at the infusion site are the characteristic problem of pulsatile therapy; the comparison meta-analysis found fewer oestrogen-related effects (gynaecomastia, acne) than with gonadotropin injections.
Human trials exist and mostly agree, but there are too few of them, they are too small, or one big one is still reading out. Expect the grade to move.
- 1Wei C, Long G, Zhang Y, et al. Spermatogenesis of male patients with congenital hypogonadotropic hypogonadism receiving pulsatile gonadotropin-releasing hormone therapy versus gonadotropin therapy: a systematic review and meta-analysis.World J Mens Health, 2021;39(4):654–6657 studies, 420 men; mostly non-randomised.
In context
Gonadorelin is synthetic gonadotropin-releasing hormone, the ten-amino-acid signal the hypothalamus sends to make the pituitary release LH and FSH. Given in pulses by pump it restores fertility in men and women whose own signal is missing; given once it is a licensed test of pituitary function. Neither is what it is mostly sold for today: clinics add it to testosterone replacement to 'keep the testes working', a use that has never been tested in a trial. It is prohibited for male athletes.
Gonadorelin (GnRH) is licensed (diagnostic / pulsatile); trt use unstudied. Legal status differs by country — see the regulation section or the jurisdiction pages.
Questions
Is Gonadorelin (GnRH) proven to cause adverse effects?
What studies are behind the grade?
Is Gonadorelin (GnRH) approved for this?
Other outcomes for Gonadorelin (GnRH)
- ALH and FSH release (diagnostic)Approval-grade
- BFertility in hypogonadotropic hypogonadism (pulsatile pump)7 comparative studies, 420 men (meta-analysis); many small series
- DPreserving testicular function on testosterone therapyNone
Written and maintained by LYO Research — how pages are written and checked. Reviewed 10 September 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →